Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital, Prato, ItalyBackground: The aim of this study was to evaluate the proportion of patients with ankylosing spondylitis maintaining clinical remission...
Guardado en:
Autores principales: | Nannini C, Kaloudi O, Cassara E, Niccoli L, Cantini F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3c9d4177edc443b28634ccfca2efa3e1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
por: Cantini F, et al.
Publicado: (2012) -
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Fabrizio Cantini, et al.
Publicado: (2009) -
Management of ankylosing spondylitis with infliximab
por: Éric Toussirot, et al.
Publicado: (2009) -
Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach A, et al.
Publicado: (2014) -
Advances in nanomedicine for the treatment of ankylosing spondylitis
por: Xi Y, et al.
Publicado: (2019)